StreetInsider.com News Articles

Precision Peptide Company plans up to $2 million private placement

Thu, 11 Jun 2026 17:02:10 -0400

The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) announced plans to raise between $1.5 million and $2 million through a private placement of common shares. The Vancouver-based wellness company intends to issue between 3 million and 4 million shares at $0.50 per share.

The offering will be conducted under Canada's listed issuer financing exemption and is available to residents of all Canadian provinces except Quebec. Shares issued under this exemption will not be subject to a hold period under Canadian securities laws.

The company stated it will use net proceeds for general working capital, advancing business objectives, funding marketing initiatives, and

The Precision Peptide Company Inc. Announces up to $2 Million LIFE Offering of Common Shares

Thu, 11 Jun 2026 17:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 11, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC") is pleased to announce that it intends to undertake a non-brokered private placement of a minimum of 3,000,000 and up to 4,000,000 common shares in the capital of the Company (the "Shares") at a price of $0.50 per Share for minimum gross proceeds of $1,500,000 and up to $2,000,000 (the "Offering").

The Offering is being completed pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 - Prospectus Exemptions, as amended by Coordinated Blanket Order 45-935

The Precision Peptide Company Inc. Announces up to $2 Million LIFE Offering of Common Shares

Thu, 11 Jun 2026 17:00:00 -0400

The Offering is being completed pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 - Prospectus Exemptions, as amended by Coordinated Blanket Order 45-935

The Precision Peptide Company Establishes Compliant U.S. Peptide Access with Telehealth and Prescription Infrastructure Partnership

Tue, 09 Jun 2026 07:30:00 -0400

Highlights

Signed an agreement with a U.S.-based prescription telehealth and infrastructure partner to support compliant prescribing, fulfillment, and delivery of the Company's peptide products
Builds on the Company's recently announced 503A compounding agreement, under which all peptides -including BPC-157- are to be 100% compounded in the United States
Partner platform is trusted by more than 100 telehealth brands and is designed to align with U.S. legal, HIPAA, and pharmacy regulations
Connects licensed provider networks across all 50 U.S. states with prescription and pharmacy fulfillment workflows
Supports a compliant, nationwide U.S. infrastructure for prescription-based peptide access ahead of anticipated U.S. regulatory developments

Vancouver, British Columbia--(Newsfile Corp. -

The Precision Peptide Company Establishes Compliant U.S. Peptide Access with Telehealth and Prescription Infrastructure Partnership

Tue, 09 Jun 2026 07:30:00 -0400

Highlights

Signed an agreement with a U.S.-based prescription telehealth and infrastructure partner to support compliant prescribing, fulfillment, and delivery of the Company's peptide products
Builds on the Company's recently announced 503A compounding agreement, under which all peptides -including BPC-157- are to be 100% compounded in the United States
Partner platform is trusted by more than 100 telehealth brands and is designed to align with U.S. legal, HIPAA, and pharmacy regulations
Connects licensed provider networks across all 50 U.S. states with prescription and pharmacy fulfillment workflows
Supports a compliant, nationwide U.S. infrastructure for prescription-based peptide access ahead of anticipated U.S. regulatory developments

Vancouver, British Columbia--(Newsfile Corp. -

The Precision Peptide Company Inc. Announces Extension of Investor Relations Agreement with Emerging Markets Consulting, LLC

Fri, 05 Jun 2026 07:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), is pleased to announce that, further to its news release dated October 15, 2025, it has extended its existing agreement with Emerging Markets Consulting, LLC ("EMC") for the continued provision of investor relations and communication services by EMC for an additional six month term.

Emerging Markets Consulting, LLC

Based in Orlando, Florida, EMC brings multiple decades of combined experience in the investor relations industry. EMC is an international investor relations firm with affiliates around the world. EMC is relationship-driven and results-oriented

The Precision Peptide Company Inc. Announces Extension of Investor Relations Agreement with Emerging Markets Consulting, LLC

Fri, 05 Jun 2026 07:30:00 -0400

Emerging Markets Consulting, LLC

Precision Peptide signs US compounding pharmacy agreement

Tue, 02 Jun 2026 07:02:14 -0400

The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) announced it has entered into a compounding agreement with a U.S.-based 503A sterile compounding pharmacy for prescription-based preparation and fulfillment of peptide products, including BPC-157.

Under the agreement, all peptides will be compounded in the United States in accordance with regulatory requirements governing 503A sterile compounding pharmacies. The compounding partner will provide access to infrastructure with capacity to fulfill up to approximately 25,000 prescriptions per day across all U.S. states.

Compounding activities are expected to commence June 1, 2026, following completion of onboarding and integration between the parties. The company did not disclose

The Precision Peptide Company Inc. Signs Agreement with U.S.-Based 503A Sterile Compounding Pharmacy - Peptides to be 100% Compounded in the United States

Tue, 02 Jun 2026 07:00:00 -0400

Highlights

Executed compounding agreement with a U.S.-based 503A sterile compounding pharmacy partner
Compounding activities under the agreement expected to commence on Monday, June 1, 2026
All peptides under the agreement to be 100% compounded in the United States
Designed to support prescription-based peptide preparation and fulfillment, including BPC-157
Up to approximately 25,000 prescriptions per day in fulfillment capacity available under the agreement, with reach across all U.S. states
Strengthens the Company's U.S. supply chain and regulatory footprint
Comes amid recent U.S. regulatory developments advancing clarity around peptide substances, including the FDA's referral of multiple peptides to the Pharmacy Compounding Advisory Committee (PCAC) for evidence-based evaluation

Vancouver, British Columbia--(Newsfile

The Precision Peptide Company Inc. Signs Agreement with U.S.-Based 503A Sterile Compounding Pharmacy - Peptides to be 100% Compounded in the United States

Tue, 02 Jun 2026 07:00:00 -0400

Highlights

Executed compounding agreement with a U.S.-based 503A sterile compounding pharmacy partner
Compounding activities under the agreement expected to commence on Monday, June 1, 2026
All peptides under the agreement to be 100% compounded in the United States
Designed to support prescription-based peptide preparation and fulfillment, including BPC-157
Up to approximately 25,000 prescriptions per day in fulfillment capacity available under the agreement, with reach across all U.S. states
Strengthens the Company's U.S. supply chain and regulatory footprint
Comes amid recent U.S. regulatory developments advancing clarity around peptide substances, including the FDA's referral of multiple peptides to the Pharmacy Compounding Advisory Committee (PCAC) for evidence-based evaluation

Vancouver, British Columbia--(Newsfile

The Precision Peptide Company to Exhibit as the Only Peptide Company at Dave Asprey's BEYOND Conference in Austin, Texas

Thu, 28 May 2026 07:30:00 -0400

Highlights

Only peptide company exhibiting at BEYOND 2026, Dave Asprey's flagship biohacking, longevity, and consciousness conference
Three immersive days in Austin, Texas — May 27-29, 2026
5,000+ attendees, 100+ speakers, 150+ exhibiting partners, and 30 experiential "hacktivations"
Dedicated booth showcasing the Company's peptide product line, including the needle-free BPC-157 transdermal patch
Event comes ahead of the previously announced feature of CSO Justin Kirkland on The Human Upgrade with Dave Asprey, airing in June 2026

Vancouver, British Columbia--(Newsfile Corp. - May 28, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and

The Precision Peptide Company to Exhibit as the Only Peptide Company at Dave Asprey's BEYOND Conference in Austin, Texas

Thu, 28 May 2026 07:30:00 -0400

Highlights

Only peptide company exhibiting at BEYOND 2026, Dave Asprey's flagship biohacking, longevity, and consciousness conference
Three immersive days in Austin, Texas — May 27-29, 2026
5,000+ attendees, 100+ speakers, 150+ exhibiting partners, and 30 experiential "hacktivations"
Dedicated booth showcasing the Company's peptide product line, including the needle-free BPC-157 transdermal patch
Event comes ahead of the previously announced feature of CSO Justin Kirkland on The Human Upgrade with Dave Asprey, airing in June 2026

The Precision Peptide Company Inc. Places Order for 20,000 BPC-157 Transdermal Patches

Tue, 26 May 2026 07:30:00 -0400

Highlights

Order placed for 20,000 units of the Company's lead product candidate, a needle-free BPC-157 transdermal patch, in preparation for commercial release
Initial commercial release of the BPC-157 transdermal patch could begin as early as June 2026 through The Precision Peptide Company website
Each patch is formulated to deliver 2 mg of BPC-157, consistent with the 95.5% chromatographic purity and 2.02 mg measured dose per patch independently confirmed in the Company's May 19, 2026 news release

Vancouver, British Columbia--(Newsfile Corp. - May 26, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on

The Precision Peptide Company Inc. Places Order for 20,000 BPC-157 Transdermal Patches

Tue, 26 May 2026 07:30:00 -0400

Highlights

Order placed for 20,000 units of the Company's lead product candidate, a needle-free BPC-157 transdermal patch, in preparation for commercial release
Initial commercial release of the BPC-157 transdermal patch could begin as early as June 2026 through The Precision Peptide Company website
Each patch is formulated to deliver 2 mg of BPC-157, consistent with the 95.5% chromatographic purity and 2.02 mg measured dose per patch independently confirmed in the Company's May 19, 2026 news release

Vancouver, British Columbia--(Newsfile Corp. - May 26, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on

The Precision Peptide Company (BPC) Expands on Exclusive 50/50 Revenue Share Peptide Partnership with MMA.INC (MMA)

Thu, 21 May 2026 07:30:00 -0400

Exclusive Agreement Gives Precision Direct Commercial Access to MMA.INC's Global Combat Sports Ecosystem, Backed by Strategic Advisors Conor McGregor and Donald Trump Jr., Cofounder John Kavanagh and Board Director Laura Sanko

Highlights

Exclusive access to MMA.INC's global combat sports ecosystem¹ of 5M+ social media followers, 530,000 user profiles and 800+ verified gyms across 16 countries
MMA.INC's roster includes strategic advisors Conor McGregor (who was announced this week to headline UFC 329 against Max Holloway on July 11, 2026 in his first UFC appearance in five years²) and Donald Trump Jr., cofounder John Kavanagh and board director and UFC commentator Laura Sanko
50/50 net

The Precision Peptide Company (BPC) Expands on Exclusive 50/50 Revenue Share Peptide Partnership with MMA.INC (MMA)

Thu, 21 May 2026 07:30:00 -0400

Highlights

Exclusive access to MMA.INC's global combat sports ecosystem¹ of 5M+ social media followers, 530,000 user profiles and 800+ verified gyms across 16 countries
MMA.INC's roster includes strategic advisors Conor McGregor (who was announced this week to headline UFC 329 against Max Holloway on July 11, 2026 in his first UFC appearance in five years²) and Donald Trump Jr., cofounder John Kavanagh and board director and UFC commentator Laura Sanko
50/50 net

The Precision Peptide Company (BPC) Expands on Exclusive 50/50 Revenue Share Peptide Partnership with MMA.INC (MMA)

Thu, 21 May 2026 07:30:00 -0400

Highlights

Exclusive access to MMA.INC's global combat sports ecosystem¹ of 5M+ social media followers, 530,000 user profiles and 800+ verified gyms across 16 countries
MMA.INC's roster includes strategic advisors Conor McGregor (who was announced this week to headline UFC 329 against Max Holloway on July 11, 2026 in his first UFC appearance in five years²) and Donald Trump Jr., cofounder John Kavanagh and board director and UFC commentator Laura Sanko
50/50 net

The Precision Peptide Company (BPC) Expands on Exclusive 50/50 Revenue Share Peptide Partnership with MMA.INC (MMA)

Thu, 21 May 2026 07:30:00 -0400

Highlights

Exclusive access to MMA.INC's global combat sports ecosystem¹ of 5M+ social media followers, 530,000 user profiles and 800+ verified gyms across 16 countries
MMA.INC's roster includes strategic advisors Conor McGregor (who was announced this week to headline UFC 329 against Max Holloway on July 11, 2026 in his first UFC appearance in five years²) and Donald Trump Jr., cofounder John Kavanagh and board director and UFC commentator Laura Sanko
50/50 net

Precision Peptide's BPC-157 patch achieves 95.5% purity in lab tests

Tue, 19 May 2026 07:02:37 -0400

The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) announced that its BPC-157 transdermal patch achieved 95.5% chromatographic purity in independent laboratory testing, meeting industry standards for high-purity peptide products.

Miraxis Labs, a San Diego-based analytical laboratory, conducted the testing using Ultra High-Performance Liquid Chromatography with Diode Array Detection. The results were certified by two PhD scientists and confirmed a quantified dose of 2.02 mg of BPC-157 per patch.

The purity result meets the 95% threshold recognized across the peptide industry as the benchmark for credible high-purity grade peptide products. The patch is designed as a needle-free, wearable product intended to deliver

The Precision Peptide Company (BPC) Lead Product Achieves 95.5% Purity in Independent Lab Testing, Clearing the Industry Benchmark and Advancing Toward Commercial Launch

Tue, 19 May 2026 07:00:00 -0400

Highlights

The BPC-157 patch is a wearable, needle-free product, designed to remove the injection barrier that has historically limited consumer adoption of peptide products
Results support The Precision Peptide Company Inc.'s continued progression of its lead product toward commercial launch
Independent lab results confirm 95.5% chromatographic purity and a quantified 2.02 mg dose of BPC-157 per patch¹
Purity result clears the ≥95% threshold recognized across the peptide industry as the analytical benchmark for credible high purity grade peptide products²
Testing performed by independent US analytical laboratory Miraxis Labs (San Diego, California), using Ultra High-Performance Liquid Chromatography with Diode Array Detection (UHPLC-DAD), and certified by two

The Precision Peptide Company (BPC) Lead Product Achieves 95.5% Purity in Independent Lab Testing, Clearing the Industry Benchmark and Advancing Toward Commercial Launch

Tue, 19 May 2026 07:00:00 -0400

Highlights

The BPC-157 patch is a wearable, needle-free product, designed to remove the injection barrier that has historically limited consumer adoption of peptide products
Results support The Precision Peptide Company Inc.'s continued progression of its lead product toward commercial launch
Independent lab results confirm 95.5% chromatographic purity and a quantified 2.02 mg dose of BPC-157 per patch¹
Purity result clears the ≥95% threshold recognized across the peptide industry as the analytical benchmark for credible high purity grade peptide products²
Testing performed by independent US analytical laboratory Miraxis Labs (San Diego, California), using Ultra High-Performance Liquid Chromatography with Diode Array Detection (UHPLC-DAD), and certified by two

The Precision Peptide Company's Chief Scientific Officer Justin Kirkland to Be Featured on The Human Upgrade with Dave Asprey

Thu, 14 May 2026 07:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 14, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that Justin Kirkland, Co-Founder and Chief Scientific Officer of the Company's wholly-owned subsidiary Amino Innovations, will be featured as a guest on an upcoming episode of The Human Upgrade with Dave Asprey.

The Human Upgrade, hosted by Dave Asprey, is a platform in the biohacking, longevity, and human performance space, with a global audience built over more than a decade of conversations on health optimization,

The Precision Peptide Company's Chief Scientific Officer Justin Kirkland to Be Featured on The Human Upgrade with Dave Asprey

Thu, 14 May 2026 07:30:00 -0400

MMA.INC partners with Precision Peptide in 50/50 revenue share deal

Tue, 12 May 2026 08:31:50 -0400

Mixed Martial Arts Group Limited (NYSE American: MMA) announced an exclusive marketing partnership with The Precision Peptide Company Inc. (CSE: BPC; OTCQB: PNGAF) to sell peptide recovery products across its global combat sports network.

Under the agreement, MMA.INC will receive 50% of net revenue from sales generated through its platform during the first twelve months, followed by 25% of net revenue for the remainder of the partnership term. The company will market Precision's U.S.-manufactured and third-party tested peptide products through its ecosystem of platforms including TrainAlta, BJJLink, and MixedMartialArts.com.

The partnership can be terminated by either party with 30 days written notice.

MMA.INC partners with Precision Peptide in 50/50 revenue share deal

Tue, 12 May 2026 08:31:50 -0400

The partnership can be terminated by either party with 30 days written notice.